CNTX (Context Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)


CNTX Context Therapeutics Inc CNTX
30 GF Score
Price $0.58
! 1 Warning Sign
View Full Analysis

What is Context Therapeutics OCF Margin %?

Context Therapeutics CNTX -10.14% 30 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates CNTX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, Context Therapeutics ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Context Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-11.43 Mil. Context Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Context Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Context Therapeutics's current OCF Yield % is -61.95%.

The historical rank and industry rank for Context Therapeutics's OCF Margin % or its related term are showing as below:


CNTX's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Context Therapeutics OCF Margin % Related Terms

Context Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Context Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Context Therapeutics OCF Margin % Chart

Context Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Context Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CNTX
30GF Score
Context Therapeutics Inc CNTX
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Context Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Context Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-26.385/0
= %

Context Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-11.429/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Context Therapeutics (CNTX) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Context Therapeutics and its competitors. According to the industry distribution chart, Context Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry.
Is Context Therapeutics' OCF Margin % too high?
Context Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Context Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Context Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Context Therapeutics' OCF Margin % compare to TARA and NVCT?
According to the Biotechnology industry distribution chart, Context Therapeutics ranks #999999 out of 959 companies for OCF Margin %. This places Context Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Context Therapeutics and its competitors. Context Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Context Therapeutics stock overvalued right now?
Context Therapeutics (CNTX) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Context Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Context Therapeutics (CNTX), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Context Therapeutics Business Description

Other Exchanges 6K9:Germany
Address 2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
30GF Score

Get the complete analysis for CNTX

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.58
Price